Chemotherapy as initial management of patients with operable colorectal cancer.
The evidence in support of the concepts of PrCh and of anticoagulation in the management of primary CRCa are briefly presented. The first study incorporating both these novel approaches to the treatment of CRCa with a minimum follow-up of 5 years is herein presented. Whereas no discernible differences on survival were documented on a long-term basis, when patient who ultimately recurred in each group were compared, a substantial and statistically significant prolongation of the free-of-disease interval from surgery to recurrence and of survival from recurrence to death are revealed. PRCa and anticoagulation appear to deserve further study, in the management of operable CRCa.
D000925:Anticoagulants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D003131:Combined Modality Therapy; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery
D000925:Anticoagulants; D000970:Antineoplastic Agents